FindTrial
Sign In

The Clinical Efficacy and Cognitive Inpairment of MECT on Patients with Bipolar Disorder/Unipolar Depression/Schizophrenia

A national multi-center cohort study of current status of modified electroconvulsive therapy for severe mental disorders and cognitive impairment in China

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063896
Enrollment
Unknown
Registered
2022-09-20
Start date
2022-09-20
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder/Unipolar Depression/Schizophrenia

Interventions

Exprimental Group:MECT

Sponsors

Shenzhen Kangning Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Met the diagnostic criteria for bipolar disorder/major depressive disorder/schizophrenic episode in the DSM-5. 2. informed consent and voluntary participation in this study.

Exclusion criteria

Exclusion criteria: 1. Unwilling to participate. 2. Patients with a history of serious physical disease, organic brain disease, traumatic brain injury or brain surgery, or epilepsy. 3. Patients who have contraindications to MRI (e.g., metallic objects in the body or severe claustrophobia). 4. Women in pregnancy.

Design outcomes

Primary

MeasureTime frame
Depression severity;fMRI image;Mania severity;Sleep quality;Rumination;Schizophrenia symptom severity;Childhood trauma;Self dignity;Emotion regulation;Cognition;environment;parent-child relationship;alexithymia;hopelessness;loneliness;Peer bullying;Non-suicidal self-injury;—

Countries

China

Contacts

Public ContactZhou Yongjie
qingzhu1108@126.com13927416401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026